Andrew Kowalski1, Armand Krikorian1, Edgar V Lerma2. 1. Department of Internal Medicine, University of Illinois at Chicago College of Medicine and Advocate Christ Medical Center, Oak Lawn, IL. 2. Section of Nephrology, Department of Internal Medicine, University of Illinois at Chicago College of Medicine and Advocate Christ Medical Center, Oak Lawn, IL.
Abstract
BACKGROUND: Diabetic nephropathy is the leading cause of renal disease in the United States, occurring in 20%-40% of patients with diabetes. This condition is a distinct manifestation of diabetic renal disease seen in patients with type 1 and type 2 diabetes. Despite clear screening and management recommendations, diabetic nephropathy remains substantially underdiagnosed. METHODS: This review presents recent guidelines and recommendations from varied work groups to identify, monitor, and halt the progression of diabetic nephropathy. Our search of the recent literature focused on diagnostic criteria, the latest screening recommendations, novel screening methods, current research, new treatment recommendations, and goals for early intervention. RESULTS: Current recommendations for early detection and treatment of diabetic nephropathy include yearly albumin to creatinine ratio checks and more frequent tests if indicated based on glomerular filtration rate and albuminuria; optimizing glucose control with a target hemoglobin A1c goal of <7%; initiating angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) as the first line in disease management with dual therapy of ACE inhibitors and ARBs no longer recommended; managing blood pressure with a goal of <140/90 mmHg as the target for all patients with diabetes; and initiating statin therapy for patients <50 years old and with concomitant chronic kidney disease and diabetes and in all patients with chronic kidney disease >50 years of age regardless of the coexistence of diabetes. CONCLUSION: With early detection, proper screening, and management, the impact of diabetic nephropathy may be better mitigated to lessen its impact on society and healthcare.
BACKGROUND:Diabetic nephropathy is the leading cause of renal disease in the United States, occurring in 20%-40% of patients with diabetes. This condition is a distinct manifestation of diabetic renal disease seen in patients with type 1 and type 2 diabetes. Despite clear screening and management recommendations, diabetic nephropathy remains substantially underdiagnosed. METHODS: This review presents recent guidelines and recommendations from varied work groups to identify, monitor, and halt the progression of diabetic nephropathy. Our search of the recent literature focused on diagnostic criteria, the latest screening recommendations, novel screening methods, current research, new treatment recommendations, and goals for early intervention. RESULTS: Current recommendations for early detection and treatment of diabetic nephropathy include yearly albumin to creatinine ratio checks and more frequent tests if indicated based on glomerular filtration rate and albuminuria; optimizing glucose control with a target hemoglobin A1c goal of <7%; initiating angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) as the first line in disease management with dual therapy of ACE inhibitors and ARBs no longer recommended; managing blood pressure with a goal of <140/90 mmHg as the target for all patients with diabetes; and initiating statin therapy for patients <50 years old and with concomitant chronic kidney disease and diabetes and in all patients with chronic kidney disease >50 years of age regardless of the coexistence of diabetes. CONCLUSION: With early detection, proper screening, and management, the impact of diabetic nephropathy may be better mitigated to lessen its impact on society and healthcare.
Entities:
Keywords:
Albuminuria; diabetes mellitus; diabetic nephropathies; early diagnosis; primary health care; renal insufficiency–chronic
Authors: Richard A Chudleigh; Gareth Dunseath; William Evans; John N Harvey; Philip Evans; Richard Ollerton; David R Owens Journal: Diabetes Care Date: 2007-02 Impact factor: 19.112
Authors: William C Cushman; Gregory W Evans; Robert P Byington; David C Goff; Richard H Grimm; Jeffrey A Cutler; Denise G Simons-Morton; Jan N Basile; Marshall A Corson; Jeffrey L Probstfield; Lois Katz; Kevin A Peterson; William T Friedewald; John B Buse; J Thomas Bigger; Hertzel C Gerstein; Faramarz Ismail-Beigi Journal: N Engl J Med Date: 2010-03-14 Impact factor: 91.245
Authors: Anthony H Barnett; Stephen C Bain; Paul Bouter; Bengt Karlberg; Sten Madsbad; Jak Jervell; Jukka Mustonen Journal: N Engl J Med Date: 2004-10-31 Impact factor: 91.245
Authors: Hans-Henrik Parving; Barry M Brenner; John J V McMurray; Dick de Zeeuw; Steven M Haffner; Scott D Solomon; Nish Chaturvedi; Mathieu Ghadanfar; Nicole Weissbach; Zhihua Xiang; Juergen Armbrecht; Marc A Pfeffer Journal: Nephrol Dial Transplant Date: 2009-01-14 Impact factor: 5.992
Authors: Rafael Y Brzezinski; Inbal Etz-Hadar; Ayelet Grupper; Michal Ehrenwald; Itzhak Shapira; David Zeltser; Shlomo Berliner; Ori Rogowski; Roy Eldor; Shani Shenhar-Tsarfaty Journal: Cardiovasc Diabetol Date: 2017-06-23 Impact factor: 9.951
Authors: Rajkishor Nishad; Vazeeha Tahaseen; Rajesh Kavvuri; Manga Motrapu; Ashish K Singh; Kiranmayi Peddi; Anil K Pasupulati Journal: Front Med (Lausanne) Date: 2021-07-01